TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00493649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
Study: NCT02861846

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: profile of CSF biomarkers of AD
Description: dosage of biomarker of AD
Study: NCT02639286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 304801
Description: 300 mg of ISIS 304801 administered as SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via SC
Study: NCT02312583

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Psychoeducational online information
Description: Psychoeducational online information. During 7 weeks as a complement to the usual treatment. Participants will have access to online psychoeducational material for depression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iFightDepression online programme
Description: iFightDepression online programme. During 7 weeks as a complement to the usual treatment.~Participants will complete the modules of a structured online programme for depression
Study: NCT02330614

Intervention type: OTHER
Intervention: Nothing - control group
Description: Only NEO-FFI test , data used as control
Study: NCT00806260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: Phentermine 3.75 mg and topiramate 23 mg daily for the 1st week; Phentermine 7.5 mg and topiramate 46 mg daily for the 2nd week; Phentermine 11.25 mg and topiramate 69 mg daily for the 3rd week; Phentermine 15 mg and topiramate 92 mg daily for the 4th week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: Phentermine 3.75 mg and topiramate 23 mg daily for the 1st week; Phentermine 7.5 mg and topiramate 46 mg daily for the 2nd week; Phentermine 11.25 mg and topiramate 69 mg daily for the 3rd week; Phentermine 15 mg and topiramate 92 mg daily for the 4th week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: Phentermine 3.75 mg and topiramate 23 mg daily for the 1st week; Phentermine 7.5 mg and topiramate 46 mg daily for the 2nd week; Phentermine 11.25 mg and topiramate 69 mg daily for the 3rd week; Phentermine 15 mg and topiramate 92 mg daily for the 4th week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: Phentermine 3.75 mg and topiramate 23 mg daily for the 1st week; Phentermine 7.5 mg and topiramate 46 mg daily for the 2nd week; Phentermine 11.25 mg and topiramate 69 mg daily for the 3rd week; Phentermine 15 mg and topiramate 92 mg daily for the 4th week
Study: NCT03979820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyramine
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyramine
Description: Capsules
Study: NCT00806260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo daily for 4 weeks
Study: NCT02874183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Description: Pharmacist counseling and follow-up phone calls
Study: NCT00806260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo daily for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alcohol placebo
Description: fruit juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alcohol placebo
Description: fruit juice
Study: NCT02795494

Intervention type: BEHAVIORAL
Intervention: WOMAC questionnaire at baseline
Description: Patient-reported pain, stiffness and physical function outcome score

Intervention type: BEHAVIORAL
Intervention: WOMAC questionnaire at baseline
Description: Patient-reported pain, stiffness and physical function outcome score

Intervention type: BEHAVIORAL
Intervention: ASK-P questionnaire at baseline
Description: Patient-reported activity level score

Intervention type: BEHAVIORAL
Intervention: WOMAC questionnaire at 2 weeks
Description: Patient-reported pain, stiffness and physical function outcome score
Study: NCT02171689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]- BIBW 2992 MA2
Study: NCT00038844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1 H (Alemtuzumab)
Description: Starting Dose of 15 mg by vein daily, 3 days in a row.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 by vein daily, 3 days in a row.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1 gm/m2 by vein daily, 3 days in a row.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein, given (to some patients only, based on the subtypes of lymphomas) eight days before the transplant and then weekly for a total of 4 doses.
Study: NCT03111316

Intervention type: DRUG
Group type: OTHER
Intervention: Cervidil 10 MG Vaginal Insert
Description: Dinoprostone vaginal insert is a thin, flat, polymeric slab which is rectangular in shape with rounded corners contained within the pouch of an off-white knitted polyester retrieval system, an integral part of which is a long tape. Each slab is buff colored, semitransparent and contains 10 mg of dinoprostone in a hydrogel insert. An integral part of the knitted polyester retrieval system is a long tape designed to aid retrieval at the end of the dosing interval or earlier if clinically indicated. The finished product is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
Study: NCT00126581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT00830570

Intervention type: OTHER
Intervention: CYP 2C9 and VKORC1 Testing for Warfarin
Description: Test patients for their warfarin sensitivity and provide this information to their physician authorizing the test.
Study: NCT03979820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tyramine
Description: Capsules
Study: NCT03780036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Megaprosthetic Implants the Next Generation (MING)
Description: Use of either porous of porous+hydroxyapathite collars.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Megaprosthetic Implants the Next Generation (MING)
Description: Use of either porous of porous+hydroxyapathite collars.
Study: NCT01445964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Atenolol oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Atenolol oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol with apple juice 1200 mL
Description: Atenolol oral administration with apple juice 1200 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol with apple juice 1200 mL
Description: Atenolol oral administration with apple juice 1200 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol with apple juice 600 mL
Description: Atenolol oral administration with apple juice 600 mL
Study: NCT03979820

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tyramine
Description: Capsules
Study: NCT01445964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol with apple juice 600 mL
Description: Atenolol oral administration with apple juice 600 mL
Study: NCT04037917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorNeat EverPatch
Description: Covering Ophthalmic Implants
Study: NCT02995876

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glaze layer
Description: A coating of a glaze layer will be used at the inner surface of the bridge to improve adhesion
Study: NCT03111316

Intervention type: DEVICE
Group type: OTHER
Intervention: Foley Catheter
Description: The balloon on the end of the Foley catheter will be inflated with 30 mL of sterile water, pulled back against the internal os of the cervix, and taped to the maternal thigh under minimal tension.

Intervention type: DEVICE
Group type: OTHER
Intervention: Foley Catheter
Description: The balloon on the end of the Foley catheter will be inflated with 30 mL of sterile water, pulled back against the internal os of the cervix, and taped to the maternal thigh under minimal tension.
Study: NCT02187497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of BIBR 277
Study: NCT02995876

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: E-max Press layer
Description: A coating of E-max Press layer will be used at the inner surface of the bridge to improve adhesion
Study: NCT00546572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13 valent Pneumococcal Conjugate Vaccine
Description: 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23vPS
Description: 0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1
Study: NCT02983136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialogue and inter-professional learning
Description: The middle and front-line leaders of the study OR will participate in an intervention based on an iKT model. Components of the intervention will include:~* Two workshops, consisting of educational sessions covering the state of the art regarding person-centeredness, prevention of infections, leadership, and implementation. The educational component and results of pre-studies will work as frameworks for the dialogues between the front-line leaders and the research group. In dialogues the participants will be given the opportunity to reflect on barriers to and enablers of change; and~* The participants will be supported in creating an action plan aimed at facilitating the anaesthesia providers' change of practice.
Study: NCT01781520

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC-CIK Treatment
Description: The DC-CIK cells were infused on days 15, 17, and 19 of 21-day cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK Treatment
Description: The DC-CIK cells were infused on days 15, 17, and 19 of 21-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1
Description: The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25-\<1.5 m2, 50 mg; and \>1.5 m2, 60 mg, given twice daily after meals for 14 days followed by a 7-day rest. Cycles is repeated every 21 days. Treatment is continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
Study: NCT00370890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (gemcitabine and cisplatin)
Description: Gemcitabine 1000 mg/m2 in 250 ml NS over 30 mins IV on Day 1 and 8 Cisplatin 40 mg/m2 in 1L NS over 2 h IV on Day 1 and 8 Cycle repeated every 3 weeks for total of 6 cycles
Study: NCT01606293

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Completion of online surveys taking approximately 15 - 20 minutes.
Study: NCT01178736

Intervention type: PROCEDURE
Intervention: Breast Cancer Screening and Diagnosis
Description: Clinical Breast Examination and Sonography followed by Fine needle aspiration biopsy (FNAB) of screen positive cases.

Intervention type: PROCEDURE
Intervention: Cervical Cancer Screening and Diagnosis
Description: Visual Inspection with Acetic acid, PAP smear or Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases.

Intervention type: PROCEDURE
Intervention: Ovarian Cancer Screening and Diagnosis
Description: Transvaginal sonogram and clinical evaluation in post menopausal women with symptoms suggestive of ovarian cancer.
Study: NCT02187497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose of BIBR 277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of BIBR 277
Study: NCT01128556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepreve
Description: Bepreve (bepotastine besilate ophthalmic solution 1.5%) one drop in each eye twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refresh Tears
Description: Refresh Tears one drop to each eye twice daily for 7 days after the conclusion of Bepreve treatment
Study: NCT01100671

Intervention type: OTHER
Intervention: Cross section study
Description: This is not intervention study. The purpose of the study is to examine the relationship of vascular inflammation assessed by 18FDG-PET and MDCT at the cross section setting
Study: NCT02201641

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cone Beam computed tomography (Morita Accuitomo)
Description: CBCT scans are taken to assess the efficacy of this method in detecting the presence of early peri-radicular lesions.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Periapical radiographs
Description: Periapical radiographs are taken as a control to detect the presence of early peri-radicular lesions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: calcium silicate cement (Biodentine™)
Description: calcium silicate cement (Biodentine™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: glass ionomer cement ( Fuji IX™)
Description: glass ionomer cement ( Fuji IX™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulp.
Study: NCT03158896

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCTC-0010 Dose Escalation
Description: Cohort 1: 2.0 × 106 cells per kilogram (cells/kg) body weight, given on day 0 and on day 7 in Participants having de novo High Risk Acute or Steroid Refractory Acute Graft Versus Host Disease (HR/SR aGvHD)~Cohort 2: 10 × 106 cells/kg of body weight, given on day 0 and on day 7 in Participants having de novo HR/SR aGvHD
Study: NCT04404205

Intervention type: DIAGNOSTIC_TEST
Intervention: Postural stability measurements by Biodex Balance System
Description: Postural stability measurements will be done by Biodex Balance System. Three preprogrammed main tests will be applied. Postural stability, fall index, sensory integration will be calculated. All tests will be done in four conditions; implant off(1), implant on(2), implant on music on(3), and implant off again(4).
Study: NCT02563171

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non surgical periodontal treatment
Description: 1. SRP under local anaesthesia, in a total of 2-3 clinical visits.~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non surgical periodontal treatment
Description: 1. SRP under local anaesthesia, in a total of 2-3 clinical visits.~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gingival crevicular fluid collection
Description: GCF collection with filter paper (Periopaper) using the intracrevicular method.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gingival crevicular fluid collection
Description: GCF collection with filter paper (Periopaper) using the intracrevicular method.
Study: NCT06184386

Intervention type: OTHER
Intervention: NIDCAPARENTALIM
Description: PARENTALIM practice that strengthens the NIDCAP. It is proposed in a routine way in the NICU since 2019. PARENTALIM supports and monitors parental implication in nursing care. It is led by a speach language therapist specialized in early feeding development who proposes 5 individualized interviews and uses an educational booklet on eating development care with a lot of illustrations and few words.
Study: NCT01781520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25-\<1.5 m2, 50 mg; and \>1.5 m2, 60 mg, given twice daily after meals for 14 days followed by a 7-day rest. Cycles is repeated every 21 days. Treatment is continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care
Description: Best supportive care
Study: NCT01047930

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Each 3-day experimental period will include one of the following conditions:~1. Morning exercise - subject will exercise on each of the three mornings in the sleep laboratory, starting 30 minutes after their habitual rise-time;~2. Evening exercise - subject will start exercise 4 hours before their habitual bedtime on each of the three evenings;~3. No exercise - subject will watch television or read and they will be required to remain sedentary.
Study: NCT02606175

Intervention type: OTHER
Group type: OTHER
Intervention: Taking questionnaires and tests
Description: At predefined timepoints:~* 2 tests for health literacy: New Vital Sign-Dutch version (NVS-D) and Functional, Communicative and Critical Health Literacy (FCCHL)~* 1 test for medication adherence: BAASIS~* 1 questionnaire about demographic factors (weight, income, sex, age, financial situation,...)~* 1 test about medication knowledge
Study: NCT04982874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Description: Administered with 240 mL of water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lasix® 40 mg Tablet
Description: Administered with 240 mL of water
Study: NCT00925899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 20 mg melatonin orally every evening about 1 hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of melatonin followed by one week of placebo, or the other way around), the participant may receive melatonin for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet orally every evening about one hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of placebo followed by one week of melatonin, or the other way around), the participant may receive melatonin for 6 weeks.
Study: NCT06184386

Intervention type: BEHAVIORAL
Intervention: SOFS
Description: SOFS is a behavioral practice of orofacial stimulations. Il has been mainly carried out by nurses or a speach language therapist specialized in early feeding development. SOFS has been applied through routine protocol in the NICU until 2018.
Study: NCT01389388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: All the patients who have signed the informed consent will after they have had performed a MCT and possibly SCC with an IVUS, will be give Rosuvastatinuntill their LDL level has reached 1.6-1.8 mmol/l. The objective is that all the participants should have reached 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
Study: NCT00295607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: immunosuppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: steroids, monoclonal anti-IL2R antibody
Description: immunosuppression
Study: NCT03730610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Subjects are required to exercise four times a week during six months. Exercise training consists of endurance training, resistance training and high-intensity interval training adjusted to subject's fitness level.
Study: NCT01352286

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous Genetically modified T cells
Description: Patients will undergo myeloma restaging at days +42, +100, 6 months, 9 months and 1 year post infusion. At this point, in accordance with FDA Guidelines, all patients will enter long term follow up (LTFU) and be followed biannually for monitoring for gene transfer delayed adverse events until year 5 post infusion. From year 5, all patients will require annual LTFU visits for monitoring for delayed adverse events until year 15 after receiving the genetically modified T cells.~Patients whose disease progresses prior to year 1 will enter LTFU at time of progression; however these patients will be seen quarterly from progression until year 1 post infusion and then follow the LTFU schedule mentioned above.